Met Life Investment Management, LLC Global Blood Therapeutics, Inc. Transaction History

Met Life Investment Management, LLC

$17.1 Billion
Q3 2024

36 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 10, 2024	BUY	$32.4 - $68.18 $20,768 - $43,703	641 Added 1.93%	33,813 $2.3 Million
Q3 2022 Jun 14, 2023	BUY	$32.4 - $68.18 $1.1 Million - $2.31 Million	33,813 New	33,813 $2.3 Million
Q3 2022 Mar 22, 2023	BUY	$32.4 - $68.18 $20,768 - $43,703	641 Added 1.93%	33,813 $2.3 Million
Q3 2022 Nov 14, 2022	BUY	$32.4 - $68.18 $20,768 - $43,703	641 Added 1.93%	33,813 $2.3 Million
Q2 2022 May 10, 2024	SELL	$22.3 - $37.39 $27,451 - $46,027	-1,231 Reduced 3.58%	33,172 $1.06 Million
Q2 2022 Jun 20, 2023	BUY	$22.3 - $37.39 $739,735 - $1.24 Million	33,172 New	33,172 $1.06 Million
Q2 2022 Mar 22, 2023	SELL	$22.3 - $37.39 $27,451 - $46,027	-1,231 Reduced 3.58%	33,172 $1.06 Million
Q2 2022 Aug 11, 2022	SELL	$22.3 - $37.39 $27,451 - $46,027	-1,231 Reduced 3.58%	33,172 $1.06 Million
Q1 2022 May 10, 2024	BUY	$25.68 - $35.59 $883,469 - $1.22 Million	34,403 New	34,403 $1.19 Million
Q1 2022 Jun 20, 2023	BUY	$25.68 - $35.59 $883,469 - $1.22 Million	34,403 New	34,403 $1.19 Million
Q1 2022 Mar 22, 2023	BUY	$25.68 - $35.59 $326,058 - $451,886	12,697 Added 58.5%	34,403 $1.19 Million
Q1 2022 May 12, 2022	BUY	$25.68 - $35.59 $326,058 - $451,886	12,697 Added 58.5%	34,403 $1.19 Million
Q4 2021 Jun 21, 2023	BUY	$24.9 - $40.26 $540,479 - $873,883	21,706 New	21,706 $635,000
Q3 2021 Jun 21, 2023	BUY	$25.48 - $37.34 $553,068 - $810,502	21,706 New	21,706 $553,000
Q2 2021 May 17, 2024	BUY	$32.46 - $43.42 $704,576 - $942,474	21,706 New	21,706 $760,000
Q2 2021 Jun 21, 2023	BUY	$32.46 - $43.42 $704,576 - $942,474	21,706 New	21,706 $760,000
Q2 2021 Mar 22, 2023	SELL	$32.46 - $43.42 $75,988 - $101,646	-2,341 Reduced 9.74%	21,706 $760,000
Q2 2021 Aug 16, 2021	BUY	$32.46 - $43.42 $704,576 - $942,474	21,706 New	21,706 $760,000
Q2 2020 Aug 14, 2020	SELL	$48.73 - $81.82 $1.17 Million - $1.97 Million	-24,047 Closed	0 $0
Q1 2020 Jul 12, 2023	BUY	$41.72 - $87.2 $1 Million - $2.1 Million	24,047 New	24,047 $1.23 Million
Q1 2020 Mar 22, 2023	SELL	$41.72 - $87.2 $56,029 - $117,109	-1,343 Reduced 5.29%	24,047 $1.23 Million
Q1 2020 May 15, 2020	SELL	$41.72 - $87.2 $56,029 - $117,109	-1,343 Reduced 5.29%	24,047 $1.23 Million
Q4 2019 Jul 12, 2023	BUY	$45.7 - $81.86 $1.16 Million - $2.08 Million	25,390 New	25,390 $2.02 Million
Q3 2019 Jul 12, 2023	BUY	$45.35 - $57.91 $1.15 Million - $1.47 Million	25,390 New	25,390 $1.23 Million
Q3 2019 Mar 22, 2023	BUY	$45.35 - $57.91 $103,987 - $132,787	2,293 Added 9.93%	25,390 $1.23 Million
Q3 2019 Nov 14, 2019	BUY	$45.35 - $57.91 $103,987 - $132,787	2,293 Added 9.93%	25,390 $1.23 Million
Q2 2019 Jul 12, 2023	BUY	$52.6 - $63.29 $1.29 Million - $1.55 Million	24,432 New	24,432 $1.29 Million
Q1 2019 Jul 13, 2023	BUY	$39.99 - $53.48 $923,649 - $1.24 Million	23,097 New	23,097 $1.22 Million
Q4 2018 Jul 13, 2023	BUY	$31.54 - $46.67 $728,479 - $1.08 Million	23,097 New	23,097 $948,000
Q4 2018 Mar 22, 2023	SELL	$31.54 - $46.67 $401,788 - $594,529	-12,739 Reduced 35.55%	23,097 $948,000
Q4 2018 Feb 14, 2019	SELL	$31.54 - $46.67 $401,788 - $594,529	-12,739 Reduced 35.55%	23,097 $948,000
Q3 2018 Jul 13, 2023	BUY	$38.0 - $51.1 $877,686 - $1.18 Million	23,097 New	23,097 $877,000
Q3 2018 Mar 22, 2023	BUY	$38.0 - $51.1 $1.36 Million - $1.83 Million	35,836 New	35,836 $1.36 Million
Q3 2018 Nov 14, 2018	BUY	$38.0 - $51.1 $484,082 - $650,962	12,739 Added 55.15%	35,836 $1.36 Million
Q2 2018 Aug 15, 2018	BUY	$38.7 - $50.15 $213,469 - $276,627	5,516 Added 31.37%	23,097 $1.04 Million
Q4 2017 Feb 15, 2018	BUY	$29.7 - $45.7 $522,155 - $803,451	17,581	17,581 $692,000

Others Institutions Holding GBT

# of Institutions

Shares Held

288K

Call Options Held

Put Options Held

View Full List

About Global Blood Therapeutics, Inc.

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

More about GBT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Account